177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 98 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR This 11-Year-Old Is Starting College Next Year With A Plan To... December 31, 2021 Themes in Improving Supportive Care for People With Cancer: 2022 MASCC... September 1, 2022 Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 Does Eating Processed Meat Increase Your Risk for Cancer? September 19, 2023 Load more HOT NEWS Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... FDA Approves New Interchangeable Biosimilar to Pertuzumab ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)
